During the second day of the 36th Annual J.P. Morgan Healthcare Conference, Amgen and Mylan highlighted their progress with biosimilar therapies, while Roche and Sanofi focused on progress with innovator products and combinations that may help insulate them from biosimilar and follow-on competition.
During the second day of the 36th Annual J.P. Morgan Healthcare Conference, Amgen and Mylan highlighted their progress with biosimilar therapies, while Roche and Sanofi focused on progress with innovator products and combinations that may help insulate them from biosimilar competition.
Amgen’s Biosimilars Portfolio Eyes a Share of $65 Billion in Global Sales
Amgen’s chairman and CEO, Bob Bradway, reported that biosimilars will provide an important driver of Amgen’s long-term growth; in addition to launching its adalimumab biosimilar (Amjevita) in the European Union during 2018, and receiving an approval for its bevacizumab biosimilar (Mvasi) last year, Amgen has filed its ABP 980 (trastuzumab) biosimilar for regulatory approval, and is in phase 3 development of ABP 710 (infliximab) and ABP 798 (rituximab) biosimilars.
Amgen is in phase 1 development of an eculizumab biosimilar, and process development of a cetuximab biosimilar, as well as 3 additional molecules. In total, the originator drugs that Amgen’s biosimilars are targeting totaled approximately $65 billion in worldwide sales in 2017, said Bradway.
At the same time, Amgen expects that it will be able to retain a substantial hold on market share for 2 of its originator biologics that face upcoming biosimilar competition. Bradway reported that Amgen’s reference pegfilgrastim (Neulasta) has seen strong success with its Onpro kit, sales of which accounted for 60% of Neulasta sales in the fourth quarter of 2017.
Bradway also noted that Amgen continues to “make strategic investments” in its originator etanercept (Enbrel), which will retain its US patent exclusivity through 2029, despite the approval of a biosimilar, Erelzi.
Mylan: Pegfilgrastim Biosimilar a Potential “Mid-Year 2018 Opportunity”
In a “fireside chat” presentation, Heather Bresch, Mylan’s CEO, and Rajiv Malik, company president, also highlighted progress with biosimilars. Bresch noted Mylan’s 2017 win with the approval of “our Herceptin,” Mylan’s Ogivri.
Bresch, saying that her company has one of the most robust biosimilar pipelines in the industry, did note that the market for biosimilars—as well as for generics like the multiple sclerosis drug glatiramer acetate (Copaxone), which she said was in a similar “bucket” with respect to marketplace challenges—will present a steep industry learning curve as US states address issues of substitution of drugs. Ultimately, she said, “affordability and access is going to drive necessity” for these products.
Malik added that Mylan’s pegfilgrastim biosimilar, which received a complete response letter from the FDA in October 2017, may be a “mid-year 2018 opportunity” for FDA approval. Malik said that “we believe that our mostly scientific issues have bene addressed,” and that the quality issues related to its manufacturing facility have been resolved.
Roche Looks to Combinations for Herceptin, Rituxan
Roche, maker of numerous biologics targeted by biosimilar developers, noted its December 2017 approval of pertuzumab (Perjeta) plus trastuzumab (Herceptin) in HER2-positive early breast cancer, a combination that could help the company to forestall competition from Mylan’s biosimilar trastuzumab when launched.
Additionally, with oncoming biosimilar competition for its reference rituximab, Rituxan, Roche highlighted positive results of studies of its polatuzumab vedotin plus bendamustine versus rituximab plus bendamustine in phase 2 study in treating B-cell malignancies. It also reports that its development program of venetoclax includes venetoclax plus rituximab versus bendamustine plus rituximab in patients with chronic lymphoid leukemia, acute myeloid leukemia, non-Hodgkin lymphoma, and multiple myeloma.
Roche also noted the successful recent launch of its multiple sclerosis drug ocrelizumab (Ocrevus), saying that the therapy has achieved a “broad base of prescribers and a high level of US insurance coverage,” as well as the potential of its atezolizumab (Tecentriq) to achieve new therapeutic combinations by 2020. Tecentriq is currently under investigation for combination with such drugs as bevacizumab (Avastin) for the treatment of non-small cell lung cancer.
Sanofi Eyes Sotagliflozin in the Face of Follow-on Insulin Competition in the Diabetes Market
Olivier Brandicourt, CEO of Sanofi, highlighted the company’s work on sotagliflozin for the treatment of type 1 and type 2 diabetes. Sanofi has faced substantial competition for its insulin products in the United States since Boehringer Ingelheim launched its follow-on insulin glargine (Basaglar), and now finds 2 of its patents for its reference product under review by the US Patent Trial and Appeal Board after a challenge by Mylan.
According to Brandicourt, Sanofi showed steady financial performance despite its decline in diabetes sales (expected to total 6% to 8% for the 2015 to 2018 period), but nevertheless, the company sees sotagliflozin as promising on its positive data showing weight reduction, improved time in range in type 1 diabetes, strong glycated hemoglobin reduction, and reduction in the number postprandial glucose excursions, with no increase in hypoglycemia.
BioRationality—The Evolution of the BPCIA and the Bright Future of Biosimilars in the US
October 7th 2024The Biologics Price Competition and Innovation Act (BPCIA) of 2010 initially posed significant barriers to biosimilar development, but regulatory reforms over the years have drastically reduced costs and approval times, with further advancements expected by 2025 that will foster competition and drive down prices.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Eye on Pharma: EC Approved Ustekinumab; Zymfentra Expansion; Biosimilar Policy Briefing
September 26th 2024The European Commission (EC) approved Celltrion's ustekinumab biosimilar for chronic inflammatory diseases, Celltrion expanded access to Zymfentra (subcutaneous infliximab-dyyb) through partnerships with Cigna and Express Scripts, and the Association for Accessible Medicines held a policy briefing addressing barriers to biosimilar adoption.